La Habana, Cuba

José Enrique Montero Casimiro


 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2017

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: José Enrique Montero Casimiro: Innovator in Tumor Treatment

Introduction: José Enrique Montero Casimiro is a distinguished inventor based in La Habana, Cuba. He has made significant contributions to the field of pharmaceuticals, particularly focusing on innovations for the treatment of malignant tumors. His work is vital for advancing therapeutic strategies against cancer, particularly for tumors expressing specific targets.

Latest Patents: Montero Casimiro holds a patent for his groundbreaking invention titled "Pharmaceutical compositions for the treatment of tumors expressing EGFR and GM3 N-glycolyl ganglioside (NeuGcGM3)." This invention is crucial for the treatment of malignant tumors as it enhances therapeutic effects through the utilization of antibodies and vaccines directed against EGFR and GM3 N-glycolyl ganglioside. The patent outlines methods for applying these pharmaceutical compositions effectively, marking a notable advancement in oncological treatments.

Career Highlights: José Enrique Montero Casimiro is employed at the Centro de Inmunología Molecular, an esteemed research institution dedicated to innovative medical science. Throughout his career, Montero Casimiro has remained committed to advancing cancer treatment through his innovative research, emphasizing the importance of targeted therapies in modern oncology.

Collaborations: During his professional journey, Montero Casimiro has collaborated with notable colleagues, including Adys González Palomo and Adriana Carr Pérez. This collaboration fosters a dynamic environment for innovation, enhancing the development of effective treatments through shared expertise and insights.

Conclusion: José Enrique Montero Casimiro stands out as a prominent inventor in the pharmaceutical realm, particularly in the pursuit of enhanced treatments for tumors. His dedication to research and innovation at Centro de Inmunología Molecular underscores his commitment to improving patient outcomes. With his patent on pharmaceutical compositions, he continues to pave the way for future discoveries in cancer therapy.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…